Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Other Non-current Assets
Long-term assets not reported separately.
Maze Therapeutics, Inc.NASDAQ: MAZE
Other Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Other non-current assets rises 66.6% from a year ago
Other non-current assets stood at $5.41M at the end of Q1 FY2026, up 66.6% from a year earlier and up 30.8% from the prior quarter. Over 3 fiscal years it compounded at +44.5% a year.
Context
- Other non-current assets amounted to 1.3% of total assets at the end of Q1 FY2026, up 0.3 pp from a year earlier.
- Other non-current assets increased in 1 of the last 3 fiscal years.
What to watch
Whether other non-current assets keeps rising in the next quarterly balance sheet after a +66.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 4.14M USD
- Year-over-year change
- -47.4%
- 3-year CAGR
- +44.5%
| Period | Period end | Other Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.14M | -47.4% |
| FY2024 | 2024-12-31 | 7.87M | +494.9% |
| FY2023 | 2023-12-31 | 1.32M | -3.5% |
| FY2022 | 2022-12-31 | 1.37M | — |
Other Non-current Assets vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so other non-current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +66.6% is the 3rd highest of 7, against a peer median of +18.6%.
- Other non-current assets amounts to 1.3% of total assets for MAZE, versus a peer median of 0.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $116.2M USD | +26.1% | +63.0% | 23.0% | |
SEPNSepterna, Inc. | Sep 2026 | $88.45M USD | +6190.8% | +421.4% | 14.3% |
| Sep 2026 | $40.14M USD | -5.0% | -12.8% | 4.7% | |
| Jun 2026 | $21.58M USD | -0.9% | -27.8% | 0.7% | |
| Mar 2026 | $5.41M USD | +66.6% | +44.5% | 1.3% | |
BIOABioAge Labs, Inc. | Mar 2026 | $1.9M USD | +692.9% | +453.9% | 0.5% |
| Dec 2025 | €1.16M EUR | +11.0% | +6.3% | 0.5% | |
| Mar 2026 | $400K USD | — | — | 0.8% | |
| Peer median (excluding MAZE) | — | +18.6% | +34.6% | 0.8% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.